Courtagen Life Sciences, Inc. Appoints Thomas Fairfield To The Company's Board Of Directors.

WOBURN, Mass.--(BUSINESS WIRE)--Courtagen Life Sciences, Inc., a commercial-stage, innovative molecular information company that sells proprietary genomic diagnostic and drug metabolism assays for pediatric neurology disorders, announced today the appointment of Thomas Fairfield to the company's Board of Directors.

"Tom has a wealth of legal, M&A, and operating experience," states Brian McKernan, Chief Executive Officer of Courtagen. "We look forward to adding Tom's valuable perspectives to our Board of Directors."

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.